Natixis Insmed Inc Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$22.0 - $69.71 $670,120 - $2.12 Million	30,460 Added 432.67%	37,500 $2.51 Million
Q1 2024 May 13, 2024	BUY	$25.72 - $29.94 $181,068 - $210,777	7,040 New	7,040 $190,000
Q2 2023 Aug 11, 2023	BUY	$16.44 - $21.1 $263,040 - $337,600	16,000 New	16,000 $337,000
Q4 2022 Feb 13, 2023	BUY	$16.98 - $23.15 $4.67 Million - $6.37 Million	275,000 New	275,000 $5.49 Million
Q4 2021 Feb 14, 2022	SELL	$25.89 - $33.45 $3.24 Million - $4.19 Million	-125,323 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$24.17 - $36.01 $927,813 - $1.38 Million	-38,387 Reduced 23.45%	125,323 $3.57 Million
Q1 2021 May 14, 2021	SELL	$32.28 - $44.3 $6.43 Million - $8.83 Million	-199,213 Reduced 54.89%	163,710 $5.58 Million
Q4 2020 Feb 12, 2021	BUY	$31.45 - $40.54 $11.4 Million - $14.7 Million	362,923 New	362,923 $12.1 Million

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.